Stemming the Tide of HIV/AIDS
Mylan’s commitment to fighting HIV/AIDS is an integral part of our mission and business. In fact, 50% of our API manufacturing capacity is dedicated to ARVs, which we sell in more than 100 countries. More than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world’s HIV+ children – depend on one of our products. In 2017 we maintained our position as the world’s largest producer by volume of ARVs.
On Sept. 21, 2017, at the U.N., Mylan announced its next step in the fight against the HIV epidemic. Together with partners such as the Clinton Health Access Initiative, UNAIDS, the Bill & Melinda Gates Foundation and the U.K.’s Department for International Development, Mylan entered into a unique public/private partnership to accelerate the availability of a next-generation ARV treatment, TLD, to patients in more than 90 low- and middle-income countries. As part of this alliance, Mylan committed to selling this product (a combination tablet, taken once daily, of the three molecules Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate) to public-sector purchasers at about $75 per person per year.4
Read our infectious disease fact sheet
We are building a robust portfolio of hepatitis C (HCV) drugs based on knowledge and experience derived from our HIV/AIDS work. In 2017 Mylan had active/pending registrations in approximately 50 countries.
In 2017 Mylan entered into a license agreement with Otsuka Pharmaceuticals to commercialize Delamanid (Deltyba®), a novel drug used to treat pulmonary multi-drug resistant tuberculosis (MDR-TB) in low- and middle-income countries.
We continue to look for opportunities to expand access and affordability of anti-malarials, especially in low- and middle-income countries. Mylan was the first manufacturer to receive WHO PQ for a higher-strength dose of Artemether Lumefantrine (40mg/240mg). It reduces the number of tablets required by 50% and may improve patient adherence, which may impact health outcomes.